Eli Lilly has launched TuneLab, an AI-powered platform that provides biotech companies access to drug discovery models trained on over $1 billion worth of the pharmaceutical giant’s proprietary research data. The platform aims to democratize AI capabilities in drug development, allowing smaller companies to leverage the same advanced tools used by Lilly’s scientists while contributing their own data to enhance the system.
Why this matters: The pharmaceutical industry is increasingly turning to AI to accelerate drug discovery and reduce costs, with analysts projecting AI-related R&D spending to reach $30-40 billion by 2040 as companies seek faster, cheaper alternatives to traditional development methods.
How it works: TuneLab operates on datasets representing experimental data from hundreds of thousands of unique molecules, creating AI models that can predict drug behavior and effectiveness.
- Selected biotech partners gain access to Lilly’s AI capabilities in exchange for contributing their own training data to enhance the platform.
- The system is designed to level the playing field between large pharmaceutical companies and smaller biotech firms that lack extensive research databases.
- Partners can use the platform for various applications, from cancer therapy development to small molecule discovery.
Who’s already on board: Two privately held companies have announced partnerships with Lilly for TuneLab access.
- Circle Pharma will use the platform to develop cancer therapies.
- Insitro plans to build new AI models that will be integrated into TuneLab for discovering small molecule therapies.
What they’re saying: “Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists,” said Daniel Skovronsky, Lilly’s chief scientific officer.
The bigger trend: This launch aligns with an FDA push to reduce animal testing in drug development, as AI technologies offer alternative methods for safety testing and efficacy prediction that could transform how new medications reach patients.
Recent Stories
DOE fusion roadmap targets 2030s commercial deployment as AI drives $9B investment
The Department of Energy has released a new roadmap targeting commercial-scale fusion power deployment by the mid-2030s, though the plan lacks specific funding commitments and relies on scientific breakthroughs that have eluded researchers for decades. The strategy emphasizes public-private partnerships and positions AI as both a research tool and motivation for developing fusion energy to meet data centers' growing electricity demands. The big picture: The DOE's roadmap aims to "deliver the public infrastructure that supports the fusion private sector scale up in the 2030s," but acknowledges it cannot commit to specific funding levels and remains subject to Congressional appropriations. Why...
Oct 17, 2025Tying it all together: Credo’s purple cables power the $4B AI data center boom
Credo, a Silicon Valley semiconductor company specializing in data center cables and chips, has seen its stock price more than double this year to $143.61, following a 245% surge in 2024. The company's signature purple cables, which cost between $300-$500 each, have become essential infrastructure for AI data centers, positioning Credo to capitalize on the trillion-dollar AI infrastructure expansion as hyperscalers like Amazon, Microsoft, and Elon Musk's xAI rapidly build out massive computing facilities. What you should know: Credo's active electrical cables (AECs) are becoming indispensable for connecting the massive GPU clusters required for AI training and inference. The company...
Oct 17, 2025Vatican launches Latin American AI network for human development
The Vatican hosted a two-day conference bringing together 50 global experts to explore how artificial intelligence can advance peace, social justice, and human development. The event launched the Latin American AI Network for Integral Human Development and established principles for ethical AI governance that prioritize human dignity over technological advancement. What you should know: The Pontifical Academy of Social Sciences, the Vatican's research body for social issues, organized the "Digital Rerum Novarum" conference on October 16-17, combining academic research with practical AI applications. Participants included leading experts from MIT, Microsoft, Columbia University, the UN, and major European institutions. The conference...